secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001558370-24-007476
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MeiraGTx Q1 net loss narrows to $20.4M; receives $50M milestone from Janssen
----------------------------------------------------------------------------

- Net loss attributable to shareholders $20.4M ($0.32 per share) vs $30.4M ($0.62) in Q1 2023.
- Cash and cash equivalents $119.2M at March 31; $138.9M after April collections; runway into Q1 2026.
- Received $50M milestone from Janssen for Phase 3 LUMEOS extension study initiation for bota-vec in XLRP.
- Phase 1 AQUAx data showed 112.8% increase in unstimulated saliva flow at 12 months; pivotal Phase 2 enrolling.
- Completed dosing in Phase 1 bridging study for AAV-GAD Parkinson's gene therapy; Phase 3 design discussions in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000155837024007476/0001558370-24-007476-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000155837024007476/mgtx-20240509x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-007476

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer